<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798976</url>
  </required_header>
  <id_info>
    <org_study_id>20210312</org_study_id>
    <nct_id>NCT04798976</nct_id>
  </id_info>
  <brief_title>Personalized Evidence-based Treatment in Patients With Invasive Breast Cancer</brief_title>
  <official_title>Personalized Evidence-based Treatment Improves Survival in Patients With Invasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center of Personalized Medicine, Pirogova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for New Medical Technologies, Novosibirsk, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center of Personalized Medicine, Pirogova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A population-based case-cohort study of breast cancer-specific survival among all first&#xD;
      invasive breast cancer cases&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of guideline-consistent and personalized EBM recommendations</measure>
    <time_frame>3-year</time_frame>
    <description>The percentage of guideline-consistent and personalized EBM recommendations acted on by clinicians in patients with first invasive breast cancer. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-consistent therapy and personalized EBM therapy will be adjudicated by core laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific survival</measure>
    <time_frame>3-year</time_frame>
    <description>All deaths due to breast cancer-related causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify the performance of the CDSS (MedicBK) algorithm</measure>
    <time_frame>3-year</time_frame>
    <description>Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors</measure>
    <time_frame>3-year</time_frame>
    <description>Predictors of guideline-consistent and personalized EBM adherence</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer-specific Survival</condition>
  <arm_group>
    <arm_group_label>CDSS (MedicBK) Analysis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Laboratory Analysis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant/adjuvant therapy</intervention_name>
    <description>chemotherapy/endocrine therapy/surgery/radiotherapy</description>
    <arm_group_label>CDSS (MedicBK) Analysis</arm_group_label>
    <arm_group_label>Core Laboratory Analysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All first invasive breast cancer cases from a National Cancer Registry&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All women with stage I-III disease who survived at least 12 months post-diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Unknown cause of death Treatment outside the region (thus precluding the treatment&#xD;
        assessment)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evgeny Pokushalov, Prof. MD PhD</last_name>
    <phone>89139254858</phone>
    <email>e.pokushalov@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina Ostanina, MD</last_name>
    <phone>+79039031563</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evgeny Pokushalov</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Pokushalov, Prof. MD PhD</last_name>
      <phone>89139254858</phone>
      <email>e.pokushalov@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center of Personalized Medicine, Pirogova</investigator_affiliation>
    <investigator_full_name>Evgeny Pokushalov</investigator_full_name>
    <investigator_title>Director for research and development</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

